Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris
Kohn CG, Parker MW, Limone BL, Coleman CI

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24560062

DOI
10.1016/j.amjcard.2014.01.407

Indexing Status
Subject indexing assigned by NLM

MeSH
Acetanilides /administration & dosage /economics /therapeutic use; Angina, Stable /drug therapy /economics; Chronic Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Costs; Enzyme Inhibitors /administration & dosage /economics /therapeutic use; Female; Follow-Up Studies; Humans; Male; Piperazines /administration & dosage /economics /therapeutic use; Quality-Adjusted Life Years; Ranolazine; Standard of Care /economics; United States

AccessionNumber
22014011458

Date bibliographic record published
15/04/2014